X
Xiaohui Wang
Publications - 4
Citations - 22
Xiaohui Wang is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has co-authored 1 publications.
Papers
More filters
Journal ArticleDOI
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
Bryan T. Oronsky,Xiaoning Guo,Xiaohui Wang,Pedro Cabrales,David J. Sher,Lou Cannizzo,Bob Wardle,Nacer Abrouk,Michelle Lybeck,S. Scott Caroen,Arnold L. Oronsky,Tony R. Reid +11 more
TL;DR: In this paper, RRx-001, a first-in-class dinitroazetidine small molecule, was selected for advancement into preclinical and clinical development, and is currently in phase 2 and 3 clinical trials for the treatment of multiple solid tumor malignancies and as a supportive care drug.
Journal ArticleDOI
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)
Bryan Oronsky,Nacer Abrouk,Scott Caroen,Michelle Lybeck,Xiaoning Guo,Xiaohui Wang,Zhong-Hua Yu,Tony R. Reid +7 more
TL;DR: This review surveys approved drugs and select up-and-coming ones in development for extensive stage SCLC, which finds itself in the eye of the storm, that is, at the epicenter of an intense flurry and ferment of activity, not all of it positive.
Journal ArticleDOI
Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
TL;DR: A case of advanced gastric adenocarcinoma with multiple hepatic metastases who was treated with apatinib plus paclitaxel as second-line therapy realized a long progression-free survival of 37 months, and it is believed that the good outcome is not an accident.
Journal Article
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trials.
Xiaoning Guo,Xiaohui Wang,Sui Shen,Bryan Oronsky,Tony R. Reid,Meaghan Stirn,Scott Caroen,Franck Brinkhaus,Nacer A Abrouk,Liandai Yang,Lianzong Wu +10 more
TL;DR: Evaluated patients with Asian ancestry received 4 mg of RRx-001 in three different antitumor clinical trials with chemotherapy and/or radiation and a retrospective subset efficacy and toxicity analysis was conducted, finding no apparent differences in terms of safety and efficacy.